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Abstract
Background—Systemic anthrax is associated with high mortality. Current national guidelines, 
developed for the individualized treatment of systemic anthrax, outline the use of combination 
intravenous antimicrobials for a minimum of two weeks; bactericidal and protein synthesis 
inhibitor antimicrobials for all cases of systemic anthrax; and at least 3 antimicrobials with good 
blood-brain barrier penetration for anthrax meningitis. However, in an anthrax mass casualty 
incident, large numbers of anthrax cases may create challenges in meeting antimicrobial needs.
Methods—To further inform our understanding of the role of antimicrobials in treating systemic 
anthrax, a systematic review of the English language literature was conducted to identify cases of 
systemic anthrax treated with antimicrobials for which a clinical outcome was recorded.
Results—A total of 149 cases of systemic anthrax were identified (cutaneous [n=59], 
gastrointestinal [n=28], inhalation [n=26], primary anthrax meningitis [n=19], multiple routes 
[n=9], and injection [n=8]). Among the identified 59 cases of cutaneous anthrax, 33 were 
complicated by meningitis (76% mortality), while 26 simply had evidence of the systemic 
inflammatory response syndrome (4% mortality); 21 of 26 (81%) of this latter group received 
monotherapy. Subsequent analysis regarding combination antimicrobial therapy was restricted to 
the remaining 123 cases of more severe anthrax (overall 67% mortality). Recipients of 
combination bactericidal and protein synthesis inhibitor therapy had a 45% survival versus 28% in 
the absence of combination therapy (p = 0.07). For meningitis cases (n=77), survival was greater 
for those receiving a total of ≥3 antimicrobials over the course of treatment (3 of 4; 75%), 
compared to receipt of 1 or 2 antimicrobials (12 of 73; 16%) (p = 0.02). Median parenteral 
antimicrobial duration was 14 days.
Conclusion—Combination bactericidal and protein synthesis inhibitor therapy may be 
appropriate in severe anthrax disease, particularly anthrax meningitis, in a mass casualty incident.
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Introduction
In 2014 CDC published updated national guidelines on the clinical management of anthrax 
[1–3]. These practice guidelines outline the use of combination intravenous (IV) 
antimicrobials in the treatment of systemic anthrax. Treatment regimens are defined by 
clinical manifestations of disease and involve two sets of recommendations – one for 
treatment of individuals with confirmed, or suspected anthrax meningitis (or for instances 
where meningitis cannot be ruled out), and one for individuals in whom meningitis has been 
ruled out. Both recommendations call for intravenous treatment that includes at least one 
bactericidal agent combined with a protein synthesis inhibitor; in the setting of meningitis, 
the addition of a third, preferably bactericidal, antimicrobial agent is recommended [2]. 
Bactericidal agents with good blood-brain barrier penetration recommended for the 
treatment of suspected or confirmed anthrax meningitis include quinolones, carbapenems, 
and if the isolate is susceptible, β-lactams such as penicillin G and ampicillin [2].
Regarding protein synthesis inhibitors, options include linezolid as the preferred agent 
because of high central nervous system (CNS) concentrations while acceptable alternatives 
include clindamycin, rifampin and, if linezolid, clindamycin, and rifampin are unavailable, 
chloramphenicol. For non-meningitis, systemic anthrax (which includes inhalation anthrax 
and other forms of anthrax with systemic involvement), recommendations also include 
vancomycin as a potential bactericidal agent and doxycycline as an alternative protein 
synthesis inhibitor [2]. Combination intravenous antimicrobials are recommended for a 
minimum of two weeks for patients with systemic anthrax. This is consistent with findings 
from a systematic review of inhalation anthrax cases from the pre-antimicrobial era (1900) 
to 2005, where survivors were significantly more likely to have received a multi-drug 
antimicrobial regimen [4]. Cutaneous anthrax without systemic involvement historically is 
associated with a substantially lower mortality and thus oral monotherapy is considered 
adequate [2]. Combination antimicrobial therapy for cutaneous anthrax is recommended for 
cases with systemic signs or symptoms (e.g., systemic inflammatory response syndrome), or 
cutaneous disease involving the head/neck, or associated with significant edema [2]. These 
recommendations were developed as Best Practices recommendations for the treatment of an 
individual (or small number of) patient(s) [2] (herein referred to as Best Practices guidance). 
However, an anthrax mass casualty incident has the potential to produce hundreds of 
thousands of patients with systemic anthrax disease. Given that the current 
recommendations advise the use of multiple intravenous antimicrobials in the treatment of 
systemic anthrax, a mass casualty event involving large numbers of affected individuals 
could result in challenges in adequately meeting intravenous antimicrobial needs. As part of 
ongoing efforts to plan for large-scale bioterrorism events, CDC is developing clinical 
guidance for an anthrax mass casualty incident. To inform such guidance, a systematic 
review of antimicrobials utilized for the treatment of anthrax was conducted to summarize 
what is known about historical survival with combination antimicrobial treatment. This 
includes an assessment of the types and combinations of antimicrobials used to treat anthrax 
as well as information on the duration of anthrax treatment.
The systematic review was conducted to identify available data regarding: 1) combining a 
bactericidal antimicrobial with a protein synthesis inhibitor in the treatment of systemic 
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anthrax disease, 2) the use of three antimicrobials for the treatment of anthrax meningitis, 
and 3) the duration of parenteral antimicrobial therapy for systemic anthrax.
Methods
Data Sources and Search Strategy
In collaboration with a CDC librarian, we conducted a systematic review of English 
literatures using the following twelve databases: Commonwealth Agricultural Bureaux 
(1973-), Cumulative Index to Nursing and Allied Health Literature (1981-), Defense 
Technical Information Center (1950-), EconLit (1886-), Embase (1988-), Federal Research 
in Progress (1930-), Global health (1910-), MEDLINE (1946-), National Technical 
Information Service (1964-), Web of Science (1980-), World Health Organization (1948-), 
and WorldCat (1967-). All databases were searched from inception through May 14, 2014 
(See Figure 1 for search terms). Additional reports were identified through reference 
searching and consultation with subject-matter experts. Recognizing that all the studies were 
non-randomized and observational in nature, the quality of the primary data analyzed in this 
review is low [5].
Study Selection
We included author-reported cases of human anthrax that were treated with antimicrobials 
described in the Best Practices document [2] and for which a final outcome of survival was 
recorded. An initial review of titles and abstracts identified from the search strategy was 
conducted by two independent reviewers. Articles with a title or abstract containing 
information pertaining to human anthrax treated with antimicrobials were selected for full-
text review. Four independent systematic reviewers then conducted full-text reviews to 
identify eligible studies based on clinical, epidemiologic, radiologic, pathologic, 
microbiologic, and other laboratory data provided in the report. Data abstraction was 
conducted in duplicate and decisions regarding inclusion of anthrax cases were adjudicated 
by a committee of clinical anthrax experts. We restricted reports of cutaneous anthrax to 
those that had evidence of systemic infection by systemic inflammatory response syndrome 
(SIRS) criteria [6, 7] or evidence of cutaneous anthrax complicated by anthrax meningitis.
Data Abstraction and Analysis
An Excel data abstraction tool was developed by the systematic reviewers. Data were 
collected for each individual for whom treatment was described. The following data 
elements were collected, when available: author, year of publication, and country of report; 
patient age and sex; type of anthrax, epidemiologic, clinical, pathologic and microbiologic 
features associated with diagnosis, evidence of systemic infection (fever, hypothermia, 
tachycardia, tachypnea, hypotension, leukocytosis or leukopenia based on age-specific 
thresholds as defined in [6, 7], and presence or absence of meningitis; antimicrobials used in 
treatment, mode of administration, antimicrobial class (bactericidal or protein synthesis 
inhibitor as defined in the Best Practices guidance [2]), total number of Best Practices [2] 
antimicrobials received during the course of treatment, combination treatment with 
bactericidal and protein synthesis inhibitor therapy (defined as any period during which 
there was concomitant receipt of a bactericidal agent and a protein synthesis inhibitor), and 
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duration of parenteral (intravenous or intramuscular (IM) antimicrobial treatment; and 
outcome (lived or died). Meningitis status was classified as follows: confirmed case if 
cerebrospinal fluid (CSF) with gram positive bacilli or a positive CSF culture for B. 
anthracis; probable case if reported altered mental status, meningeal signs, focal neurologic 
deficits, coma, CSF pleocytosis, presence of CSF red blood cells, CSF xanthochromia or a 
bloody CSF profile. Due to the lack of human clinical trials and heterogeneity in treatment 
regimens, we did not perform a meta-analysis.
Descriptive epidemiology was performed on the final dataset using Excel (Microsoft, 
Redmond WA) and SAS 9.3 (Cary, NC) and, where relevant, statistical testing performed 
using Chi-square testing or Fisher’s Exact Testing for small cell sizes.
Results
One hundred forty-nine individual cases, identified in 98 articles (Figure 2; Appendix Table 
A), received an antimicrobial recommended in the Best Practices guidance [2]; had evidence 
of cutaneous disease (with systemic signs or symptoms and/or complicated by meningitis), 
GI anthrax, inhalation anthrax, injection anthrax, or primary anthrax meningitis (CNS 
disease without any other route of infection noted); and a defined outcome (survived or 
died). The cases were reported in the literature between 1945 and 2014. Over 80% of the 
cases were reported from the following 7 countries (from which ≥5 cases were reported): 
India (n=30), U.S. (n=27), Turkey (n=24), Iran (n=24), U.K. (n=9), Lebanon (n=6), and 
Zimbabwe (n=5). One hundred forty-five cases had recorded sex; 42 (29%) were female and 
103 (71%) were male. Age was recorded in 145 cases; 111 (77%) were 18 years and older 
and 34 (23%) 17 years and younger. Appendix Table A presents the evidence table 
generated from this systematic review.
Types of anthrax
The most common types of anthrax were as follows: cutaneous (with systemic signs or 
symptoms and/or meningitis) (n=59, 40%), GI (n=28, 19%), inhalation anthrax (n=26, 
17%), primary anthrax meningitis (n=19, 13%; probable n=4, confirmed n=15), multiple 
types, (n=9, 6%, such as GI and cutaneous, GI and inhalation, and GI and injection), and 
injection anthrax (n=8, 5%). Overall, 77 (52%) individuals had confirmed (n=53) or 
probable (n=24) anthrax meningitis (either as a complication following another route of 
infection or as primary CNS infection).
Thirty-three of the 59 individuals with a cutaneous route of infection met criteria for 
meningitis; of these, 25 died (76% mortality). Among the remaining 26 individuals with 
cutaneous anthrax who met SIRS criteria, 1 died (4% mortality). For the other frequently 
identified types of anthrax (n≥10 cases), mortality was reported to be 57%, 65%, and 89% 
for GI, inhalation, and primary anthrax meningitis, respectively (Table 1). Overall, 62 of 77 
individuals (81%) with either probable or confirmed anthrax meningitis (either as a 
complication following another route of infection or as primary CNS infection) died. Among 
just those with confirmed anthrax meningitis, 47 of 53 individuals [89%] died.
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In addition to the substantially lower mortality rate of the 26 individuals with systemic 
cutaneous anthrax without reported meningitis, compared to the mortality for the other 
frequently identified forms of anthrax, 21 of 26 (81%) received single drug therapy and only 
1 received overlapping bactericidal and protein synthesis inhibitor antimicrobial therapy. 
Given these observations, these individuals were not included in the subsequent analyses 
evaluating antimicrobial therapy and the remainder of the results focus on severe anthrax 
defined as all forms of anthrax other than cutaneous anthrax without secondary meningitis 
(i.e., cutaneous anthrax with secondary meningitis, inhalation, injection, GI anthrax, and 
primary anthrax meningitis).
Antimicrobial use and outcome for severe anthrax disease
Antimicrobial use, categorized as bactericidal or protein synthesis inhibitor therapy, was 
analyzed for the 123 remaining individuals, of whom 82 died (67% mortality). Among 
bactericidal agents, most cases received a penicillin class antimicrobial (n=108), followed by 
fluoroquinolones (n=27), vancomycin (n=8), or a carbapenem (n=4). For protein synthesis 
inhibitor therapy, the antimicrobials included chloramphenicol (n=20), clindamycin (n=20), 
rifampin (n=8), doxycycline (n=3), and linezolid (n=1).
In descending order, individuals received a total of 1 antimicrobial (n = 79, 64%), 2 
antimicrobials (n = 22, 18%) or ≥ 3 antimicrobials (n=22, 18%) over their treatment course 
(Table 2). By class of antimicrobials, most single agent treatment consisted of a penicillin-
class antimicrobial (74 of 79 individuals, 94%), with 42% of single agent therapy occurring 
among cases reported prior to 1990. Receipt of a single antimicrobial was associated with a 
72% mortality.
To determine the association between survival and combined bactericidal and protein 
synthesis inhibitor therapy, survival for individuals who received (at any point in their 
treatment course and for any duration) overlapping therapy with a bactericidal agent and a 
protein synthesis inhibitor was compared to individuals who received at least one Best 
Practices [2] antimicrobial but never received overlapping bactericidal and protein synthesis 
inhibitor antimicrobials. Those receiving overlapping bactericidal and protein synthesis 
inhibitor therapy had a survival rate of 45% (17 of 38 patients) compared to those not 
receiving overlapping therapy (24 of 85 patients, 28%) (p = 0.07).
Table 3 provides detailed information regarding the type and number of antimicrobials 
received during course of treatment for the 77 patients with anthrax meningitis (confirmed 
and probable), stratified by mortality. In descending order, individuals received 1 
antimicrobial (n = 54, 70%), 2 antimicrobials (n = 19, 25%) or ≥ 3 antimicrobials (n=4, 5%) 
over their treatment course. By class of antimicrobials, most single agent treatment consisted 
of a penicillin-class antimicrobial (51 of 54 individuals, 94%). Among these 77 patients, 
75% (3 of 4 patients) of those receiving a total of ≥3 antimicrobials over the course of their 
treatment survived compared to 16% (12 of 73 patients) of those who received either a total 
of 1 or 2 antimicrobials over the course of their treatment (p = 0.02). Moreover, nineteen 
individuals with probable or confirmed meningitis received, for some duration, combination 
bactericidal and protein synthesis inhibitor antimicrobial therapy. Over the course of their 
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treatment, four received a total of ≥3 antimicrobials (75% survival) and 15 received a total 
of 2 antimicrobials (7% survived) (p = 0.02).
Duration of Best Practices parenteral treatment
To determine how long to continue parenteral treatment, duration of Best Practices IV or IM 
antimicrobial therapy was assessed among those who survived anthrax. This information 
was recorded for 16 of 41 individuals. The median number of days of Best Practices IV or 
IM therapy was 14 days (range 0–30 days; 1 individual with anthrax meningitis received 10 
days of cefaperazone/sulbactam + metronidazole (which would not count toward receipt of 
an IV or IM Best Practices antimicrobial [2]), followed by 60 days oral ciprofloxacin) [8]. 
For the subset of individuals that survived confirmed or probable anthrax meningitis, 
duration of Best Practices IV or IM antimicrobial therapy was recorded for 11 of 15 
individuals and the median was 14 days (range 0–26 days).
Discussion
During an anthrax mass casualty incident, it is anticipated that individuals will present with 
inhalation anthrax from breathing in spores, cutaneous anthrax from physical contact with 
spores, and cases may be complicated by anthrax meningitis. Inhalation anthrax, anthrax 
meningitis, and cutaneous disease involving the head/neck or surrounded by significant 
edema have been reported to be associated with high mortality [4, 9, 10]. It is important to 
understand the role of combination antimicrobial regimens (in terms of number of agents 
and type of agents) for the treatment of systemic anthrax to ensure judicious and optimal use 
of antimicrobials during a mass casualty incident. On the other hand, for uncomplicated 
cutaneous anthrax, oral monotherapy should suffice and therefore this is less of a concern 
for mass event planning [2].
Before evaluating treatment regimens, we sought to understand the types of anthrax that 
have historically been most severe: inhalation anthrax and anthrax meningitis. In an earlier 
systematic review of inhalation anthrax [4], the overall mortality was 85%. Of note, that 
systematic review includes cases from 1900 through 2005, and thus includes inhalation 
anthrax cases from prior to the antimicrobial era. However, even among the 32 patients 
treated with antimicrobials, mortality remained high, at 75%. Consistent with these findings, 
our systematic review of anthrax cases treated with antimicrobials also found a high 
mortality: 70% among the 30 inhalation cases. Furthermore, in one review of 70 cases of 
anthrax meningoencephalitis, mortality was reported to be 94% [10]. In our systematic 
review, meningitis complicated 77 of 149 cases (52%) of systemic anthrax and 81% of these 
individuals died.
Combination bactericidal and protein synthesis inhibitor therapy may be appropriate in 
severe anthrax disease, particularly anthrax meningitis, as noted in the Best Practices 
guidelines [2]. In another systematic review focused on inhalation anthrax cases, including 
cases from the pre-antimicrobial era, previous investigators showed that receipt of a multi-
drug regimen was associated with decreased mortality when compared to individuals that 
did not receive such treatment (which included single drug treatment as well as no 
antimicrobial treatment) [4]. In this review of antimicrobial therapy for systemic anthrax, 
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our findings did not contradict current national guidelines, finding that among individuals 
treated with one or more Best Practices [2] antimicrobials for systemic anthrax, 45% of 
those receiving overlapping bactericidal-protein synthesis inhibitor therapy survived versus 
28% of those without any overlapping bactericidal-protein synthesis inhibitor treatment. 
Much of anthrax pathogenesis is toxin mediated, thus the finding of an added benefit of 
protein synthesis inhibition is consistent with known mechanisms of disease. In vitro data 
confirm that a protein synthesis inhibitor (linezolid) is more effective than a bactericidal 
antimicrobial (ciprofloxacin) in attenuating B. anthracis toxin production [11]. In addition, 
the use of a protein synthesis inhibitor (clindamycin) has been shown to improve clinical 
outcomes of invasive group A streptococcal infections in humans, an infection that is known 
to be associated with bacterial toxin production [12].
While the Best Practices guidance [2] calls for combination triple antimicrobial therapy for 
meningitis, there was a paucity in our dataset of cases receiving 3 or more antimicrobials for 
meningitis. Among the subset of individuals with meningitis who received, for some period 
of time, combination bactericidal and protein synthesis inhibitor therapy, a higher percent 
survival was observed for those receiving 3 or more antimicrobials versus those receiving 
only 2 antimicrobials. These recommendations are consistent with a review of the 
management of anthrax meningoencephalitis by Sejvar and colleagues, in which they 
recommend the use of a fluoroquinolone coupled with 1 or 2 other antimicrobials with good 
CNS penetration [13]. Whether the improved outcomes associated with the use of three or 
more antimicrobials over the course of treatment relates to greater likelihood of at least one 
antimicrobial crossing the blood-brain barrier, versus a synergistic antimicrobial effect, or 
some other undefined factor, remains to be elucidated.
One limitation of these data relates to the fact the reports described in this manuscript were 
from the English literature only, though we did review nearly 6,700 titles and abstracts, 
conducted nearly 400 full text reviews, and the cases included in this analysis were from a 
very wide geographic distribution. In addition, several limitations in the available data 
impede our ability to know with certainty whether improved survival was due to 
combination antimicrobial therapy, advances in critical care medicine, or other confounding 
factors, such as shorter times to treatment or ancillary treatments such as intravenous fluid. 
As all the data was observational in nature, its quality could be considered, at best, low [5]. 
The reports we reviewed contained diverse and varying levels of information, requiring 
clinical interpretation. As noted, duration of treatment was not captured in a uniform 
manner, and this was the case with other treatment related variables, such as timing of 
antimicrobial therapy and route of administration. And, the definitions used for systemic 
anthrax and anthrax meningitis were based on interpretation of reported signs, symptoms, 
and epidemiologic, radiologic, pathologic and laboratory parameters. In addition, the data 
analyzed include cases spanning a 70-year period, during which antimicrobial options and 
intensive care have changed tremendously. The primary bactericidal antimicrobials 
recommended in the Best Practices guidance (fluoroquinolones) [2] were only used in 22% 
of the severe cases of anthrax. Another first-line antimicrobial class (carbapenems) was used 
in only 3% of cases. The most frequently used antimicrobials for severe illness were 
penicillins (88% of cases) and chloramphenicol (16% of cases), the latter of which is 
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unlikely to be used in the current treatment of anthrax in the United States. In addition, these 
cases are heterogeneous, representing treatment in widely different locations, with differing 
health care capacities, and cases could have had widely varying severities of illness.
While data on total duration of parenteral therapy were sparse, they are consistent with the 
concept of a minimum of two weeks of intravenous therapy. Therapy beyond two weeks 
could not be evaluated.
The limitations and confounding factors described above must be taken into account when 
considering the results presented. And, as additional data become available regarding the use 
of newer, combination, and broader spectrum antimicrobial therapies, and in situations of 
severe antimicrobial shortages, treatment guideline developers may need to revisit whether 
fewer antimicrobials, perhaps used for a shorter time, could be effective for treating severe 
anthrax disease. These considerations are particularly relevant in the setting of a large-scale 
anthrax mass casualty incident when resource constraints may exist.
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Search Strategy
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Figure 2. 
Flow Diagram of Search Strategy
* Commonwealth Agricultural Bureaux (CAB), Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Defense Technical Information Center (DTIC), Federal 
Research in Progress (FEDRIP), National Technical Information Service (NTIS), World 
Health Organization (WHO)
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